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at least 1 risk factor for stroke (ie, a CHA2DS2­
­VASc score of ≥1 in men or ≥2 in women).2-4
Randomized controlled trials are considered 
the gold­standard method to evaluate the effec­
tiveness and safety of simple therapeutic inter­
ventions such as OAC. However, clinical trials 
have limited generalizability because they are 
IntroductIon Atrial fibrillation (AF) is 
the most common arrhythmia in clinical prac­
tice and is associated with a significant risk of 
morbidity and mortality, mainly due to an in­
creased risk of stroke and systemic embolism.1 
Prevention of embolism with oral anticoagula­
tion (OAC) is recommended for AF patients with 
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AbstrAct
IntroductIon Data on antithrombotic treatment among patients with atrial fibrillation (AF) in Poland 
are limited.
objEctIvEs We aimed to describe antithrombotic management within the Polish part of the EURO‑
observational Research Programme on Atrial Fibrillation General Long ‑Term Registry.
PAtIEnts And mEthods We analyzed data collected at baseline and at 1 ‑year follow ‑up from 701 Polish 
patients treated at 25 Polish centers between 2013 and 2016.
rEsuLts Any antithrombotic therapy was administered to 94% of patients (vitamin K antagonists [VKAs], 
53%; non ‑VKA oral anticoagulants [NOACs], 36%; antiplatelet therapy [APT], 4.8%). However, 78% of 
patients considered as “low ‑risk” (CHA2DS2 ‑VASc = 0 in men or 1 in women) were prescribed oral 
anticoagulants and 12% were on APT. Independent predictors of NOAC and VKA use were first ‑detected 
AF and device therapy. Predictors of VKA use were lone AF, history of ischemic stroke, and pulmonary 
embolism or deep vein thrombosis; of NOAC use, permanent AF; of APT use, history of hemorrhagic 
events and first ‑detected or persistent AF; and of no antithrombotic treatment, young age. Incorrect 
NOAC prescription was more common in the reduced ‑dose group than in the full ‑dose group (30% vs 7%). 
During follow ‑up, the all ‑cause mortality rate was 5.2%, 0.8%, 15%, and 7% (P <0.0001) and the risk of 
thromboembolic events was 0.4%, 0.5%, 6.2%, and 0% (P = 0.04) in patients on VKA, NOAC, APT, and 
no treatment, respectively.
concLusIons Patients with the lowest stroke risk are often overtreated. The choice of proper anti‑
thrombotic strategy does not depend solely on factors incorporated in the CHA2DS2 ‑VASc score. Higher 
mortality is observed among APT ‑treated patients and those without antithrombotic treatment.
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of the prescriptions are summarized in Supple­
mentary material (Table S1). Prescriptions that 
were classified as inappropriate solely based on 
a missing value or multiple missing values were 
reported as “unknown inappropriateness.”
Ethical approval The registry was approved by lo­
cal ethical review boards according to the regula­
tions of each participating country. The study was 
performed according to the European Union Note 
for Guidance on Good Clinical Practice CPMP/
ECH/135/95 and the Declaration of Helsinki. 
A signed informed consent was obtained from 
each patient after providing detailed informa­
tion on the registry.10
statistical analysis Data were presented as a me­
dian and interquartile range or number of pa­
tients and percentages, as appropriate. The statis­
tical significance of differences was analyzed us­
ing the Kruskal–Wallis test. Frequencies of param­
eters or events were compared using the χ2 test 
or Fisher exact test, as appropriate. For all tests, 
a P value of less than 0.05 was considered signif­
icant. To determine predictors of different type 
of antithrombotic management, univariable and 
multivariable logistic regression analyses were 
performed. Statistical analysis was performed 
with StatsModels: Statistic in Python – v0.10.1 
documentation (Seabold, Skipper, and Josef Perk­
told. “Statsmodels: Econometric and statistical 
modeling with Python.” Proceedings of the 9th 
Python in Science Conference 2010).
rEsuLts baseline characteristics Of the 701 pa­
tients enrolled, 10 were excluded due to missing 
data on antithrombotic treatment (Supplemen­
tary material, Figure S1). Any antithrombotic reg­
imens were administered during study enrollment 
to 94% of Polish patients. Vitamin K antagonists 
(VKAs) were the most commonly prescribed anti­
thrombotic drugs, followed by non ­VKA oral anti­
coagulants (NOACs), whereas antiplatelet therapy 
(APT) was administered only to a small fraction of 
Polish patients (53%, 36%, and 4.8%, respectively). 
Patients receiving various regimens of antithrom­
botic treatment differed with respect to several 
baseline characteristics. Those on APT were old­
er, had a greater prevalence of coronary artery dis­
ease (mainly in the form of myocardial infarction), 
more often had a history of heart failure, current 
malignancy, as well as more often were diagnosed 
with first ­detected or permanent AF as compared 
with the remaining patients. Patients on NOACs 
more often had persistent AF and hypertension, 
whereas those without antithrombotic treatment 
more often had lone AF as compared with the oth­
er groups. The median CHA2DS2 ­VASc and HAS­
­BLED scores were higher in patients treated with 
APT (tAbLE 1). Both patients treated with reduced 
doses of rivaroxaban and dabigatran were charac­
terized by older age, more often were female, more 
often had coronary artery disease, and had higher 
thromboembolic or bleeding risk compared with 
performed in conditions that differ from rou­
tine clinical practice.5,6 In consequence, recom­
mended OAC may be underused in a significant 
proportion of patients, but antithrombotic drugs 
can be also overprescribed in many patients.7-9
There are limited data on contemporary an­
tithrombotic treatment of patients with AF in 
Poland. Therefore, we aimed to describe anti­
thrombotic management within the Polish part 
of the EURObservational Research Programme 
Atrial Fibrillation (EORP ­AF) General Long ­Term 
Registry. Moreover, we evaluated associations be­
tween patients’ clinical characteristics and drug 
choice as well as between the type of antithrom­
botic management and long ­term outcomes.
PAtIEnts And mEthods study population Data 
reported herein are based on the results calculated 
for Polish participants of the EORP ­AF Long ­Term 
General registry, which was conducted from 2013 
to 2016. The methodology of this registry was de­
scribed previously.10 In brief, the aim of the regis­
try was to assess the rate of complications related 
to AF across Europe in order to confirm adherence 
of cardiologists to the 2012 recommendations of 
the European Cardiac Society (ESC) on the treat­
ment of AF.3 The registry population consisted of 
consecutive patients presenting to cardiologists 
with AF as the main or comorbid condition. Ad­
ditionally, patients included in the registry had to 
have AF within the last year, as recorded on elec­
trocardiography, but they did not need to be in ar­
rhythmia at the time of enrollment. Finally, 701 
consecutive patients from 25 Polish centers were 
included in the registry. Participating investiga­
tor sites presented a broad range of medical care 
units (tertiary, secondary, general hospitals, and 
outpatient clinics). The registry schedule assumed 
1 baseline visit and 1 visit per year over a 3 ­year 
follow ­up, but only data collected at baseline and 
at 1 year were included in this analysis.
Appropriateness of non–vitamin K antagonist oral 
anticoagulant dosing A prescription was report­
ed as inappropriate if the patient met at least 
1 inappropriate dosing criterion according to 
the ESC guideline for AF and the summary of 
product characteristics as registered with the Eu­
ropean Medicine Agency.11 The dosing criteria 
that were used to evaluate the appropriateness 
whAt’s nEw?
The analysis of the Polish part of EURObservational Research Programme on 
Atrial Fibrillation General Long ‑Term Registry provides an overview of atrial 
fibrillation management in Poland. Treatment with antithrombotic drugs had 
a high frequency and was associated with various clinical features. Patients 
with the lowest risk of stroke (CHA2DS2 ‑VASc = 0) were often overprescribed 
or received an inappropriate dose of antithrombotic drugs. One ‑year follow‑
‑up revealed an overall low occurrence of thromboembolic and hemorrhagic 
events, although mortality remains high, especially among patients treated 
with antiplatelet therapy alone or those without antithrombotic treatment.
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(HAS ­BLED >3) (Supplementary material, Table 
S4). However, still 78% of Polish patients who 
were considered “low ­risk” (CHA2DS2 ­VASc = 0), 
were prescribed anticoagulation and 12% were 
receiving APT (FIGurE 1). In our study, 30% of pa­
tients were prescribed lower doses of NOACs de­
spite indications for a standard dose, whereas 7% 
of patients were prescribed full instead of reduced 
NOAC doses (Supplementary material, Figure S2).
Predictors of oral antithrombotic drug use The pre­
dictors of the use of particular antithrombotic 
drugs are demonstrated in tAbLE 3. Independent 
predictors of the use of both NOACs and VKAs 
were first ­diagnosed AF and device therapy. Addi­
tionally, lone AF, history of ischemic stroke, and 
pulmonary embolism or deep vein thrombosis 
turned out to be predictors of VKA use, where­
as permanent AF was a predictor of NOAC use. 
those on full NOAC doses (tAbLE 2). Detailed char­
acteristics of patients with AF treated with differ­
ent antithrombotic regimens are presented in Sup­
plementary material, Table S2, while detailed char­
acteristics of rivaroxaban­ and dabigatran ­treated 
groups (both using standard and reduced doses) 
are shown in Supplementary material, Table S3.
thromboembolic risk, bleeding risk, and antithrombot-
ic therapy  The use of different antithrombotic 
strategies stratified by CHA2DS2 ­VASc and HAS­
­BLED scores is shown in FIGurE 1. Almost 95% 
of patients with indications (CHA2DS2 ­VASc ≥2) 
were treated with antithrombotic drugs (includ­
ing VKAs, NOACs, and APT). One ­fifth of pa­
tients with indications who received antithrom­
botic treatment and one ­fourth of those who, 
despite indications, did not receive any anti­
thrombotic drugs were at high risk of bleeding 
tAbLE 1 Clinical characteristics of patients with atrial fibrillation treated with different oral antithrombotic regimens
Variable VKA 
(n = 366)
NOAC  
(n = 249)
APT  
(n = 33)
No antithrombotic therapy 
(n = 43)
P value
Demographics
Age, y, median (IQR) 67 (61–74) 68 (61–76) 73 (63–80) 68 (51–73) 0.07
Female sex, n (%) 156 (43) 110 (44) 11 (33) 17 (40) 0.67
Atrial fibrillation
First‑diagnosed 10 (2.7); 365 24 (9.6); 248 5 (15) 2 (4.7) <0.0001
Paroxysmal 107 (29); 365 80 (32); 248 10 (30) 20 (46) 0.14
Long ‑standing persistent 38 (10); 365 20 (8); 248 1 (3) 3 (7) 0.43
Persistent 67 (18); 365 67 (27); 248 1 (3) 5 (12) 0.001
Permanent 143 (39); 365 57 (23); 248 16 (49) 13 (30) <0.0001
Lone 18 (4.9) 20 (8) 3 (9.1) 10 (23) <0.0001
Concomitant diseases and interventions
Hypertension 208 (57); 364 157 (64); 247 16 (49); 32 17 (40) 0.02
CAD 135 (39); 350 80 (34); 237 21 (64) 8 (21); 39 0.001
Previous MI 66 (19); 350 32 (14); 237 15 (46) 5 (13); 39 <0.0001
Previous PCI / PTCA 65 (19); 350 28 (12); 237 12 (36) 3 (7.7); 39 0.001
Heart failure 201 (55); 364 107 (43); 247 24 (73) 18 (42) 0.001
Dilated cardiomyopathy 35 (9.6); 364 14 (5.6); 245 3 (9.1) 3 (7) 0.37
Hypertrophic cardiomyopathy 11 (3); 364 2 (0.8); 245 0 2 (4.7) 0.15
Restrictive cardiomyopathy 0; 364 0; 245 0 1 (2.3) 0.002
Device therapy (PM / CRT / ICD) 88 (24); 361 27 (11); 248 7 (21) 4 (10); 39 <0.0001
Previous thromboembolic events 52 (14); 363 23 (9.2) 3 (9.1) 2 (4.7) 0.08
Hemorrhagic events 23 (6); 364 19 (7.6); 248 8 (24) 6 (14) 0.001
Current malignancy 4 (1.1); 360 2 (0.8) 2 (6.1) 2 (4.7) 0.03
Thromboembolic and bleeding risk, median (IQR)
CHA2DS2 ‑VASc score 3 (2–4) 3 (2–4) 4 (3–6) 3 (1–3) 0.01
HAS ‑BLED score 1.5 (1–2) 1 (0–2) 2 (1–3) 1 (0–2) 0.02
Data are presented as number (percentage) of patients unless otherwise indicated. Number provided after the semicolon indicates the total number of 
patients available for that variable.
Abbreviations: APT, antiplatelet therapy; CAD, coronary artery disease; CHA2DS2 ‑VASc, congestive heart failure, hypertension, age ≥75 years, 
diabetes mellitus, history of stroke or thromboembolism, vascular disease, age 65 to 74 years, female sex; CRT, cardiac resynchronization therapy; 
ICD, implantable cardioverter ‑defibrillator; IQR, interquartile range; HAS ‑BLED, hypertension, abnormal renal/liver function, stroke, bleeding history or 
predisposition, labile international normalized ratio, elderly, drugs / alcohol concomitantly; MI, myocardial infraction; NOAC, non–vitamin K antagonist 
oral anticoagulants; OAC, oral anticoagulation; PCI, percutaneous coronary intervention; PM, pacemaker; PTCA, percutaneous transluminal coronary 
angioplasty; VKA, vitamin K antagonist
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and noncardiovascular events as compared with 
the remaining groups (tAbLEs 4 and 5). According to 
patients on NOACs, there were no significant dif­
ferences in long ­term outcomes between the type 
of a NOAC as well as between standard or reduced 
doses (tAbLEs 6 and 7). During the 1 ­year follow ­up, 
some patients were switched from one to anoth­
er antithrombotic regimen, as shown in Supple­
mentary material, Figure S1. Among patients with­
out any antithrombotic treatment on enrollment, 
during 1 ­year follow ­up, 9 patients were started on 
VKAs; 6 patients, on NOACs (mainly dabigatran); 
and 1 patient, on APT. Among the patients treat­
ed at baseline with NOACs, 10 were switched to 
VKAs (9 patients to dabigatran and 1 patient to ri­
varoxaban) or discontinued treatment (8 patients 
on dabigatran and 10 patients on rivaroxaban). 
On the other hand, 22 patients treated with VKAs 
were switched to NOACs (11 patients to dabigatran 
and 11 to rivaroxaban), and 3 patients, to APT. In 
the APT group, the majority of patients who were 
initially treated with APT and switched to anoth­
er treatment, changed APT to VKA (5 patients).
dIscussIon The EORP ­AF General Long ­Term 
registry provides an important view on contem­
porary antithrombotic strategies used in Polish 
History of hemorrhagic events as well as first­
­diagnosed and persistent AF were all predictive 
for choosing APT, whereas young age predicted 
refraining from any antithrombotic treatment.
one -year outcomes During 1 ­year follow ­up, of 
the 691 patients enrolled, 176 patients had with­
drawn their consent or were lost to follow ­up 
and 29 patients died. One ­year all ­cause mortal­
ity rates were 5.2%, 0.8%, 15%, and 7% for pa­
tients on VKA, NOAC, APT, and no antithrom­
botic treatment, respectively (P <0.0001). Most 
patients died from a cardiovascular cause (sudden 
cardiac death or heart failure). All patients treated 
with APT or who were on no antithrombotic treat­
ment who died during follow ­up had indications 
for OAC (CHA2DS2 ­VASc >2). Patients without an­
tithrombotic treatment were more often subjected 
to cardiovascular interventions (mainly a valvular 
surgery), and those on APT, to thromboembolic 
events during follow ­up. No significant differences 
between all analyzed groups were observed regard­
ing rhythm control interventions and reasons for 
hospital admissions except more frequent general 
practitioner visits in the case of patients without 
antithrombotic treatment. Moreover, APT ­treated 
patients more often experienced thromboembolic 
tAbLE 2 Clinical characteristics of patients with atrial fibrillation depending on the dose of dabigatran or rivaroxaban
Variable Rivaroxaban Dabigatran P value
Standard 
(n = 65)
Reduced 
(n = 24)
Standard 
(n = 114)
Reduced 
(n = 46)
Demographic data
Age, y, median (IQR) 67 (62–73) 80 (75–84) 64 (57–71) 78 (70–83) <0.0001
Female sex 26 (40) 15 (63) 44 (39) 25 (54) 0.02
Atrial fibrillation
First‑diagnosed 6 (9.2); 64 2 (8.3) 14 (12) 2 (4.3) 0.28
Paroxysmal 24 (37); 64 9 (38) 34 (30) 13 (28) 0.61
Long ‑standing persistent 5 (7.7); 64 2 (8.3) 11 (9.6) 2 (4.3) 0.47
Persistent 9 (14); 64 2 (8.3) 43 (38) 13 (28) 0.001
Permanent 20 (31); 64 9 (38) 12 (11) 16 (35) <0.0001
Lone 4 (6.2) 0 14 (12) 2 (4.3) 0.15
Concomitant diseases and interventions
CAD 24 (38); 63 12 (55); 22 24 (21); 108 20 (44); 44 0.001
Previous MI 5 (7.7); 63 6 (25); 22 10 (8.8); 108 11 (24); 44 0.003
Previous PCI / PTCA 5 (7.7); 63 5 (23); 22 9 (7.9); 108 9 (20); 44 0.03
Angina 16 (25); 63 8 (36); 22 5 (4.4); 108 10 (22); 44 <0.0001
Valvular alterations moderate / severe 21 (32); 64 14 (58) 20 (18); 111 16 (35) 0.001
Previous thromboembolic events 2 (3.1) 1 (4.2) 16 (14) 4 (8.7) 0.14
Hemorrhagic events 4 (6.2); 64 2 (8.3) 7 (6.1) 6 (13) 0.26
CKD 3 (4.6) 5 (21) 12 (11) 18 (39) <0.0001
Thromboembolic and bleeding risk, median (IQR)
CHA2DS2 ‑VASc score 3 (2–4) 4 (3–5) 2 (1–4) 4 (3–5) <0.0001
HAS ‑BLED score 1 (0–2) 2 (1–2) 1 (0–2) 2 (1–2) 0.001
Data are presented as number (percentage) of patients unless otherwise indicated. Number provided after 
the semicolon indicates the total number of patients for that variable.
Abbreviations: CKD, chronic kidney disease; others, see tAbLE 1
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FIGurE 1 Proportion of 
patients treated with 
antithrombotic drugs by 
the CHA2DS2 ‑VASc 
score (A) and HAS ‑BLED 
score (b) 
Abbreviations: 
see tAbLE 1
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tAbLE 3 Regression analysis for predictors of different antithrombotic regimens
Variable Univariable analysis Multivariable analysis
OR 95% CI P value OR 95% CI P value
Predictors of NOAC use
First ‑diagnosed AF 2.66 1.4–5.07 0.003 1.97 1.00–3.84 0.047
Permanent AF 0.46 0.32–0.66 <0.0001 0.58 0.39–0.88 0.01
Device therapy (PM / CRT / ICD) 0.41 0.26–0.65 <0.0001 0.51 0.31–0.84 0.008
Predictors of VKA use
Lone AF 0.46 0.25–0.83 0.01 0.49 0.27–0.88 0.02
Ischemic stroke 2.20 1.18–4.11 0.01 4.34 1.31–14.45 0.02
Pulmonary embolism / DVT 9.15 1.17–71.89 0.04 23.06 2.29–231.85 0.008
First ‑diagnosed AF 0.27 0.13–0.55 <0.0001 0.33 0.16–0.68 0.003
Device therapy (PM / CRT / ICD) 2.38 1.57–3.61 <0.0001 1.91 1.24–2.95 0.003
Predictors of APT use
Hemorrhagic events 4.24 1.81–9.93 0.001 0.24 0.11–0.53 <0.0001
First ‑diagnosed AF 3.09 1.12–8.46 0.03 0.14 0.05–0.36 <0.0001
Persistent AF 0.12 0.02–0.86 0.04 0.01 0.01–0.06 <0.0001
Predictors of no antithrombotic treatment
Age (every 10 years) 0.76 0.62–0.94 0.01 0.96 0.95–0.87 <0.0001
Abbreviations: AF, atrial fibrillation; DVT, deep vein thrombosis; OR, odds ratio; others, see tAbLE 1
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those included in the CHA2DS2 ­VASc score. Third, 
there is no association between the type of appro­
priate antithrombotic management (VKAs or NO­
ACs) and long ­term thromboembolic and hemor­
rhagic outcomes in AF patients; however, high­
er mortality is observed among patients treat­
ed with APT only or those without antithrom­
botic treatment.
patients with AF. There are several major findings 
of the present study. First, our country ­specific 
registry data suggest overuse of antithrombotic 
treatment in a significant proportion of patients 
at low risk of stroke or systemic embolism. Sec­
ond, physicians’ clinical assessment of stroke risk 
and the subsequent choice of proper AF manage­
ment appear to incorporate also factors beyond 
tAbLE 4 Associations between the type of antithrombotic treatment and long ‑term outcomes in all study groups
Variable VKA 
(n = 366)
NOAC 
(n = 249)
APT 
(n = 33)
No antithrombotic 
treatment 
(n = 43)
P value
Follow ‑up completed 253 (69) 187 (75) 18 (55) 28 (65) 0.06
Death 19 (5.2) 2 (0.8) 5 (15) 3 (7) <0.0001
Withdrawn consent / lost to follow ‑up 94 (26) 60 (24) 10 (30) 12 (28) 0.86
Data are presented as number (percentage) of patients unless otherwise indicated.
Abbreviations: see tAbLE 1
tAbLE 5 Associations between the type of antithrombotic treatment and long ‑term outcomes among patients who presented at follow ‑up visit
Variable VKA (n = 253) NOAC (n = 187) APT (n = 18) No antithrombotic 
treatment (n = 28)
P value
Clinical visits for CV reasons during follow ‑up
Cardiology visits 208 (90); 232 147 (81); 182 13 (81); 16 19 (76); 25 0.04
Emergency room admissions 34 (15); 234 28 (15); 184 2 (13); 16 3 (12); 26 0.96
GP visits 167 (74); 225 148 (86); 172 11 (73); 15 22 (96); 23 0.006
CV interventions
Overall 26 (11); 239 5 (2.7); 184 2 (13); 16 3 (12); 26 0.01
PCI / PTCA 5 (2.1); 239 4 (2.2); 184 0 (0); 16 1 (3.8); 26 0.87
CABG 4 (1.7); 239 0 (0); 184 1 (6.2); 16 0 (0); 26 0.07
LAAO 2 (0.8); 239 0 (0); 184 0 (0); 16 0 (0); 26 0.59
Transcatheter valve intervention 2 (0.8); 239 0 (0); 184 0 (0); 16 0 (0); 26 0.59
Valvular surgery 13 (5.4); 239 0 (0); 184 1 (6.2); 16 2 (7.7); 26 0.01
Heart transplant 0 (0); 239 0 (0); 184 0 (0); 16 0 (0); 26 1.00
Other 4 (1.7); 239 1 (0.5); 184 0 (0); 16 0 (0); 25 0.63
Reasons for hospital admission
AF / AFl / AT 19 (8.2); 233 26 (14); 181 0 (0); 16 4 (15); 26 0.09
Thromboembolic events 1 (0.4); 241 1 (0.5); 183 1 (6.2); 16 0 (0); 26 0.04
Hemorrhagic events 3 (1.2); 241 3 (1.6); 183 0 (0); 16 0 (0); 26 0.87
ACS 4 (1.7); 241 2 (1.1); 183 0 (0); 16 0 (0); 26 0.83
Overall CV events 28 (12); 240 16 (8.7); 183 4 (25); 16 0 (0); 26 0.054
Non ‑CV events 8 (3.3); 240 15 (8.2); 183 3 (19); 16 1 (3.8); 26 0.02
Rhythm control interventions and device therapy
Pharmacological cardioversion 11 (4.8); 231 11 (6.2); 178 0 (0); 16 1 (4.2); 24 0.71
Electrical cardioversion 14 (6); 233 18 (10); 180 0 (0); 16 2 (8); 25 0.30
Catheter ablation for AF 5 (2.2); 231 7 (3.9); 180 0 (0); 16 1 (4); 25 0.65
Catheter ablation for AFl 1 (0.4); 232 1 (0.6); 180 0 (0); 16 1 (4); 25 0.21
AF surgery 2 (0.8); 233 0 (0); 180 0 (0); 16 0 (0); 25 0.59
Device therapy (PM / ICD / CRT) 7 (3); 233 5 (2.2); 180 0 (0); 16 1 (4); 25 0.84
Data are presented as number (percentage) of patients unless otherwise indicated. Number provided after the semicolon indicates the total number of 
patients for that variable.
Abbreviations: ACS, acute coronary syndrome; AFl, atrial flutter; AT, atrial tachycardia; CABG, coronary artery bypass graft; CV, cardiovascular; 
GP, general practitioner; LAAO, left atrial appendage occlusion; others, see tAbLEs 1–3
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8.1% in the fourth quarter of 2010 to 78.9% in 
the first quarter of 2017 and surpassed that of 
VKAs in the third quarter of 2013.13 In our study, 
among AF patients who received OAC, 41% and 
59% were treated with NOACs and VKAs, respec­
tively. It is in line with data from the CRAFT study 
For decades, VKAs were the only available OAC 
therapy in patients with AF, reducing the risk of 
stroke by almost two ­thirds.12 The introduction of 
NOACs in 2010 changed the landscape of stroke 
prevention in AF. Indeed, the proportion of inci­
dent OAC users for NOACs increased rapidly from 
tAbLE 6 Associations between standard and reduced doses of non–vitamin K oral anticoagulants and long ‑term 
outcomes among all study groups
Variable Rivaroxaban (n = 89) Dabigatran (n = 160) P value
Standard (n = 65) Reduced (n = 24) Standard (n = 114) Reduced (n = 46)
Death 1 (1.5) 0 (0) 0 (0) 1 (2.2) 0.45
Follow ‑up completed 46 (71) 17 (71) 87 (76) 37 (80) 0.64
Withdrawn consent /
lost to follow‑up
18 (28) 7 (29) 27 (24) 8 (17) 0.59
Data are presented as number (percentage) of patients unless otherwise indicated.
tAbLE 7 Associations between standard and reduced doses of non–vitamin K oral anticoagulants and long ‑term 
outcomes among patients who presented at follow ‑up visit
Variable Rivaroxaban (n = 63) Dabigatran (n = 124) P value
Standard (n = 46) Reduced (n = 17) Standard (n = 87) Reduced (n = 37)
Cardiology visits 38 (83); 44 12 (75); 16 71 (84); 85 26 (70) 0.24
Emergency room 
admissions
10 (23); 44 4 (24) 13 (15); 86 1 (2.7) 0.06
GP visits 35 (83); 42 14 (100) 68 (84); 81 31(89); 35 0.39
CV interventions
Overall 2 (4.5); 44 1 (5.9) 1 (1.2); 86 1 (2.7) 0.58
PCI / PTCA 1 (2.3); 44 1 (5.9) 1 (1.2); 86 1 (2.7) 0.67
CABG 0 (0); 44 0 (0) 0 (0); 86 0 (0) 1.00
LAAO 0 (0); 44 0 (0) 0 (0); 86 0 (0) 1.00
Transcatheter valve 
intervention
0 (0); 44 0 (0) 0 (0); 86 0 (0) 1.00
Valvular surgery 0 (0); 44 0 (0) 0 (0); 86 0 (0) 1.00
Heart transplant 0 (0); 44 0 (0) 0 (0); 86 0 (0) 1.00
Other 1 (2.3); 44 0 (0) 0 (0); 86 0 (0) 0.36
Reasons for hospital admission
AF / AFl / AT 6 (14); 44 0 (0) 15 (18); 84 5 (14); 36 0.30
Thromboembolic events 0 (0); 44 0 (0) 1 (1.2); 85 0 (0) 0.76
Hemorrhagic events 2 (4.5); 44 0 (0) 1 (1.2); 85 0 (0) 0.35
ACS 0 (0); 44 0 (0) 1 (1.2); 85 1 (2.7) 0.67
Overall CV events 3 (6.8); 44 0 (0) 9 (11); 85 4 (11) 0.50
Non ‑CV events 7 (16); 44 1 (5.9) 4 (4.7); 85 3 (8.1) 0.18
Rhythm control interventions and device therapy
Overall 8 (17) 1 (5.9) 20 (22) 4 (12) 0.36
Pharmacological 
cardioversion
3 (7); 43 1 (6.2); 16 7 (8.3); 84 0 (0); 35 0.39
Electrical cardioversion 2(4.5); 44 1 (6.2); 16 14 (17); 85 1 (2.9); 35 0.06
Catheter ablation for AF 2 (4.5); 44 0 (0); 16 4 (4.7); 85 1 (2.9); 35 0.84
Catheter ablation for AFl 0 (0); 44 0 (0); 16 0 (0); 85 1 (2.9); 35 0.19
AF surgery 0 (0); 44 0 (0); 16 0 (0); 85 0 (0); 35 1
Device therapy 
(PM / ICD / CRT)
1 (2.2); 44 0 (0); 16 3 (3.5); 85 1 (2.9); 35 0.56
Data are presented as number (percentage) of patients unless otherwise indicated. Number provided after 
the semicolon indicates the total number of patients for that variable.
Abbreviations: see tAbLEs 1–3 and 5
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Compared with our results, in the whole EORP­
­AF General Long ­Term registry, 42.1% of AF 
patients were treated with VKAs, 32.8% with 
NOACs, 7% with APT, and 6.1% received no an­
tithrombotic treatment. The registry reported 
a low occurrence of thromboembolic and hemor­
rhagic events, although mortality was high. All­
­cause death more often occurred in APT ­treated 
patients (8.8%) as compared with those on no 
antithrombotic therapy (5.1%), those on VKAs 
(4.8%), and those on NOACs (3.2%), which is in 
line with our results. Both VKAs and NOACs were 
associated with a lower risk of all main adverse 
outcomes, similarly to our study.26
Based on our study, there is still some overuse 
of antithrombotic treatment observed in real ­life 
patients with AF. Nearly 78% of patients with 
a CHA2DS2 ­VASc score of 0 in men and of 1 in 
women, who are considered “low ­risk”, received 
OAC, including 12% who received APT. This over­
use pattern of anticoagulation is higher than that 
reported in such registries as GARFIELD (Glob­
al Anticoagulant Registry in the Field; 38.7%), 
Euro Heart (49.0%), or PREFER (Prevention of 
Thromboembolic Events – European Registry; 
62.5% of ineligible patients received OAC). Almost 
95% of patients with indications for anticoagu­
lation (CHA2DS2 ­VASc ≥2) were taking at least 1 
OAC, which suggests a better adherence to recom­
mendations for OAC, as compared with the above 
studies (ie, GARFIELD, 59.3%; Euro Heart, 67%; 
PREFER, 85.6% of eligible patients received OAC).6-
8 Compared with previous data from EORP ­AF Pi­
lot where 65% of Polish patients with indications 
(CHA2DS2 ­VASc >2) and 67% of those without in­
dications (CHA2DS2 ­VASc = 0) were prescribed 
OACs,27 our results demonstrate a clear trend to­
wards more frequent OAC prescription. Also, APT 
was less frequently prescribed in patients at high 
risk of thromboembolic event (but still), as com­
pared with previous studies.6,7
Recent studies have demonstrated a strong as­
sociation between APT and an increased risk of 
all ­cause mortality.28,29 Vazquez et al29 reported 
that aspirin monotherapy was associated with 
a 66% increased likelihood of mortality. Our study 
also demonstrated that patients on APT were 
at higher risk of mortality and thromboembol­
ic events as compared with other antithrombot­
ic groups, even with patients on no antithrom­
botic treatment. Our finding of higher mortality 
in patients on no antithrombotic treatment is in 
line with previous studies.30,31
Despite differences in the mortality rate and 
thromboembolic events between study groups, 
there were no significant differences in terms 
of hemorrhagic events during follow ­up. This 
is in line with the results from the BLED ­AC 
study (Bleeding Effected by Direct Oral Antico­
agulants), which demonstrated that among pa­
tients with OAC ­related hemorrhage, in ­hospital 
mortality was lower among patients with NOAC­ 
than among those with VKA ­associated bleeding 
events (9.8% vs 15.2%). However, no significant 
(Multicentre Experience in AFib Patients Treated 
with OAC), which was recruiting Polish patients 
with AF at a similar period of time (2011–2016), 
in which 44% and 56% of patients were prescribed 
NOACs and VKAs, respectively.14 
Even though the presented findings may seem 
outdated as a rapid increase in the NOAC use has 
changed trends in prescription patterns for an­
ticoagulants with a consensual decrease of anti­
platelet drugs, they strengthen the concept that 
OAC use has significantly reduced risk for throm­
boembolic complications, without an excess of 
bleeding complications in real ­life AF population. 
Obviously, our results do not allow to reconsider 
the role of APT in thromboembolic risk manage­
ment but highlight the role of antiplatelet drugs 
in the management of concomitant vascular dis­
ease, which is often reported in AF patients.
In recent years, contemporary ESC guidelines 
have recommended prophylaxis with antithrom­
botic agents in people with AF and at least 1 
other risk factor for stroke.15-17 However, a dis­
cordance between AF guideline recommenda­
tions,3,4,18,19 educational and organizational 
barriers in the implementation of guideline­
­recommended AF,20 as well as anticoagulant 
prescription patterns has been reported in var­
ious international studies.21-25 The current study 
assessed adherence of cardiologists to the 2012 
ESC recommendations as it was conducted in 
the years 2013 to 2016. According to those guide­
lines, anticoagulation was recommended in pa­
tients with a CHA2DS2 ­VASc score of 2 or high­
er and assigned a IIa A recommendation in pa­
tients with a CHA2DS2 ­VASc score of 1. Anti­
coagulation was not recommended in patients 
with a CHA2DS2 ­VASc score of 0 (I A); however, 
it was only not considered (IIa B) in female pa­
tients without any additional risk factors. 
The current 2016 ESC guidelines4 strength­
en the usefulness of the CHA2DS2 ­VASc score 
for predicting thromboembolic risk. Anticoag­
ulation is not recommended in patients with 
a CHA2DS2 ­VASc score of 0, even in women 
(III A). Anticoagulation is assigned a IIa B rec­
ommendation in men and women with a single 
stroke risk factor and a I A recommendation 
in men with 2 or more risk factors and wom­
en with at least 3 risk factors. Thus, the female 
sex is no longer considered an independent risk 
factor when indications for anticoagulation are 
being assessed. 
Two important differences regarding anti­
thrombotic treatment in comparison with pre­
vious ESC guidelines (2012) are a clear declara­
tion of preference for NOACs over VKAs (I A) 
and the fact that APT is no more recommend­
ed for stroke prevention in AF patients, regard­
less of stroke risk (III A). Interestingly, the rec­
ommendation for a switch to a NOAC when in­
adequate control of the international normalized 
ratio is achieved with a VKA was changed from 
I B in the 2012 guidelines to IIb A in the 2016 
guidelines.
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